C-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma

International Journal of Surgical Pathology

Volumn 10, Issue 4, 2002, Pages 247-256

  Pinto de Sousa, Joao ^a,b   David, Leonor ^a,b   Almeida, Raquel ^a   Leitao, Dina ^a,b   Preto, John R ^a,b   Seixas, Mario ^a,b   Pimenta, Amadeu ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

c erb B 2 expression; Gastric carcinoma; Immunohistochemistry; Prognosis; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR; POLYCLONAL ANTIBODY; TYROSINE KINASE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CHROMOSOME 17Q; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; TISSUE SPECIFICITY; TUMOR LOCALIZATION; VENOUS CIRCULATION; CARCINOMA; FOLLOW UP; LYMPH NODE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH; STOMACH TUMOR; SURVIVAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; STOMACH; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0036817076     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/106689690201000402     Document Type: Article

References (49)

1. Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg 84:1651-1664, 1997
2. Marubini E, Bonfanti G, Bozzetti F, Borracchi P, Amadori D, Folli S, Nanni O, Gennari L. A prognostic score for patients resected for gastric cancer. Eur J Cancer 29A:845-850, 1993
3. Roder JD, Böttcher K, Siewert JR, Busch R, Hernmanek P, Meyer HJ. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 72:2089-2097, 1993
4. Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study. Ann Surg 228:449-461, 1999
5. Maehara Y, Tomada M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, Sugimachi K. Prognostic value of p53 protein expression for patients with gastric cancer-a univariate analysis. Br J Cancer 79:1255-1261, 1999
6. Roviello F, Marrelli D, Vindigni C, De Stefano A, Spine D, Pinto E. p53 accumulation is a prognostic factor in intestinal-type gastric carcinoma but not in the diffuse type. Ann Surg Oncol 6:739-745, 1999
7. Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 83:1094-1101, 1998
8. Tahara E. Miolecular biology of gastric cancer. World J Surg 19:484-488, 1995
9. Kyokane K, Ito H, Sato Y, Ina K, Kusugani K. Expression of Bcl-2 and p53 correlates with morphology of gastric neoplasia. J Pathol 184:382-389, 1998
10. Kim JH, Uhm HD, Gong SJ, Shin DH, Choi JH, Lee HR, Nosh SH, Kim BS, Cho JY, Yoo NC, Chung HC, Roh JK, Min JS, Lee Ks, Kim BS. Relationship between p53 overexpression and gastric cancer progression. Oncology 54:166-170, 1997
11. Yoo CH, Noh SH, Kim H, Lee HY, Min JS. Prognostic significance of CD44 and nm23 expression in patients with stage II and stage IIIA gastric carcinoma. J Surg Oncol 71:22-28, 1999
12. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85:1894-1902, 1999
13. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985
14. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4:362-366, 1989
15. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussen L. The neu gene: An erb-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229:976-978, 1985
16. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamaoto T. The product of the human c-erb B-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986
17. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD. Identification of heregulin, a specific activator of p185erbB2. Science 256:1205-1210, 1992
18. King CR, Krauss MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-976, 1985
19. Yokota J, Toyosima K, Sugimura T, Yamamoto T, Terada M, Battifora H, Cline MJ. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1:765-767, 1986
20. Cohen JA, Weiner DB, More KF, Kokai Y, Williams WV, Maguire HC, LiVolsi VA, Greene MI. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 4:81-88, 1989
21. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
22. Slamon DJ, Clark GM, Wong SG, Levin WY, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
23. Park JB, Rhim JS, Park SC, Kimm SW, Kraus MH. Amplification, overexpression, and rearrangement of the erb B-2 protooncogene in primary human stomach carcinomas. Cancer Res 49:6605-6609, 1989
24. David L, Seruca R, Nesland JM, Soares P, Sansonetty F, Holm R, Borresen AL, Sobrinho-Simões M. c-erb B-2 expression in primary gastric carcinomas and their metastases. Modern Pathol 5:384-390, 1992
25. Heintz NH, Leslie KO, Rogers LA, Howard OL. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 114:160-163, 1990
26. Tervahauta A, Eskelinen M, Syrjanen S, Lipponen P, Pajarinen P, Syrjanen K. Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance. Anticancer Res 11:1677-1681, 1991
27. Mokbel K, Hassanally D. From HER-2 to herceptin. Curr Med Res Opin 17:51-59, 2001
28. Duffy MJ, Biochemical markers in breast cancer: Which ones are clinically useful? Clin Biochem 34:347-352, 2001
29. Bell R. Ongoing trials with trastuzumab in breast cancer. Ann Oncol 12:S69-S73, 2001
30. Piccart MJ. Proposed treatment guidelines for HER-2-positive metastatic breast cancer in Europe. Ann Oncol 12:S89-S94, 2001
31. Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, Miyazaki I, Yamamoto H. Amplification of the c-met, c-erb B-2 and epidermal growth factor gene in human gastric cancers: Correlation to clinical features. Oncology 55:475-481, 1998
32. Gurel S, Dolar E, Yerci O, Samli B, Ozturk H, Nak SG, Gulten M, Memik F. The relationship between c-erb B-2 expression and clinicopathological factors in gastric cancer. J Int Med Res 27:74-78, 1999
33. Orita H, Maehara Y, Emi Y, Kakeji V, Baba H, Korenaga D, Sugimachi K. c-erb B-2 expression is predictive for lymphatic spread of clinical gastric carcinoma. Hepatogastroenterology 44:294-298, 1997
34. Yonemura Y, Ninomiya I, Tsugawa K, Fushida S, Fujimura T, Miyazaki I, Uchibayashi T, Endou Y, Sasaki T. Prognostic significance of c-erb B-2 gene expression in the poorly differentiated type of adenocarcinoma of the stomach. Cancer Detect Prev 22:139-146, 1998
35. Dursum A, Poyraz A, Celik B, Akyol G. Expression of c-erb B-2 oncoprotein in gastric carcinoma: Correlation with histopathological characteristics and analysis of Ki-67. Pathol Oncol Res 5:104-106, 1999
36. Polkowski W, van Sandick JW, Offerhaus GJ, ten Kate FJ, Mulder J, Obertop H, van Lanschot JJ. Prognostic value of Laurén classification and c-erb B-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 6:290-297, 1999
37. Albino AP, Jacne J, Altorki N, Blundell M, Urmacher C, Lauwers G, Nieddzwiecki D, Kelsen DP. Amplification of HER-2/neu gene in human gastric carcinomas: Correlation with primary site. Eur J Surg Oncol 21:56-60, 1995
38. Amadori D, Maltoni M, Volpi A, Nanni O, Scarpi E, Renault B, Pellegata NS, Gaudio M, Magni E, Ranzani GN. Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma. Cancer 79:226-223, 1997
39. Ortolani CM, Sundblad AS. Gastric cancer. Clinicopathological characteristics and expression of c-erb B-2 oncogene in 122 cases. Medicina (B Aires) 53:97-102, 1993
40. Siewert JR, Böttcher K, Stein HJ, Roder JD, Busch R. Problem of proximal third gastric carcinoma. World J Surg 19:523-531, 1995
41. Pinto-de-Sousa J, David L, Seixas M, Pimenta A. Clinico-pathological profiles and prognosis of gastric carcinoma from the cardia, fundus/body, and antrum. Dig Surg 18:102-110, 2001
42. Laurén P. The two histological main types of gastric carcinoma: Diffuse and the so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64:31-49, 1965
43. Carneiro F, Seixas M, Sobrinho-Simões M. New elements for an updated classification of the carcinomas of the stomach. Pathol Res Pract 191:571-584, 1995
44. Ming SC. Gastric carcinoma: A pathobiological classification. Cancer 39:2475-2485, 1977
45. Sobin LH, Wittekind Ch, (eds.) TNM classification of malignant tumors, International Union Against Cancer, 5th Ed. John Wiley & Sons, New York, 1997
46. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
47. Yonemura Y, Ninomiya I, Ohoyama S, Kimura H, Yamaguchi A, Fushida S, Kosaka T, Miwa K, Miyazaki I, Endou Y, Tanaka M, Sasaki T. Expression of c-erb B-2 oncoprotein in gastric carcinoma. Cancer 67:2914-2918, 1991
48. Yokota J, Yamamoto T, Miyajima N, Toyoshima K, Nomura N, Sakamoto H, Yoshida T, Terada M, Sugimura T. Genetic alterations of the c-erb B-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-ezbA homologue. Oncogene 2:283-287, 1988
49. Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. Relationship of c-erb B-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 72:2083-2088, 1993